Skip to main content
. Author manuscript; available in PMC: 2022 Mar 11.
Published in final edited form as: Breast Cancer Res Treat. 2020 Sep 2;184(3):689–698. doi: 10.1007/s10549-020-05884-z

Fig. 4.

Fig. 4

Prognostic performance of the 63-gene signature in high-grade serous ovarian cancer. A PFI; B DFI. RI-High high recurrence index (RI), RI-Low low recurrence index (RI)